CVRx Launches new Barostim NEO2™ Implantable Pulse Generator
03 nov. 2022 10h31 HE
|
CVRx, Inc.
The new Barostim NEO2 Implantable Pulse Generator (IPG) launches in the U.S., improving the patient experience while on therapy and simplifying the implant procedure for physicians MINNEAPOLIS, Nov. ...
CVRx to Attend Upcoming Investor Conferences
03 nov. 2022 08h30 HE
|
CVRx, Inc.
MINNEAPOLIS, Nov. 03, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation...
CVRx Reports Third Quarter 2022 Financial and Operating Results
01 nov. 2022 16h15 HE
|
CVRx, Inc.
MINNEAPOLIS, Nov. 01, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation...
CVRx to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call on November 1st, 2022
18 oct. 2022 16h30 HE
|
CVRx, Inc.
MINNEAPOLIS, Oct. 18, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation...
CVRx to Present at the Canaccord Genuity 42nd Annual Growth Conference
29 juil. 2022 08h30 HE
|
CVRx, Inc.
MINNEAPOLIS, July 29, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation...
CVRx Reports Second Quarter 2022 Financial and Operating Results
28 juil. 2022 16h10 HE
|
CVRx, Inc.
MINNEAPOLIS, July 28, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation...
CVRx to Report Second Quarter 2022 Financial and Operating Results and Host Conference Call
14 juil. 2022 16h30 HE
|
CVRx, Inc.
MINNEAPOLIS, July 14, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation...
CVRx Launches a new Barostim™ Programmer
12 juil. 2022 08h30 HE
|
CVRx, Inc.
MINNEAPOLIS, July 12, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure, has...
CVRx to Present at the William Blair 42nd Annual Growth Stock Conference
23 mai 2022 16h30 HE
|
CVRx, Inc.
MINNEAPOLIS, May 23, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation...
CVRx® Receives MR-Conditional Labeling Approval for its Barostim™ Heart Failure System
09 mai 2022 08h30 HE
|
CVRx, Inc.
Heart failure patients implanted with Barostim can now receive conditional MRI scans MINNEAPOLIS, May 09, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), developer of the world’s...